AZBio Expo 2011 Company Spotlight
The 2011 AZBio Expo brought together innovative and life saving companies from across the state along with leaders from across the industry. Be sure to check out the highlights and a special spotlight interview where Don Isaacs, VP of Communications at SynCardia Systems, Inc. brings EmpowHER's Shana O'Conner up close and personal with the world's only Total Artificial Heart. It's why SynCardia was named the 2011 Bioscience Company of the Year.
Company Presentation: Invoy Technologies, LLC
Exhaled Breath: A Portal for Pain-Free Biochemical Analysis Invoy is engaged in the development and commercialization of breath analysis devices for a broad range of applications. Invoy plans to offer patients the ability to monitor their health in the convenience of their own home – with a prescription-based breath analysis device called the Voyager. The process is pain-free and the results are quick and accurate; giving patients peace of mind and confidence in using this new-to-the-market device.
AZBio and SynCardia on ABC15
By: Christina Estes ABC15 Tucson-based SynCardia Systems was among the companies showcased at the annual AZ Bio Expo.It’s a chance for bioscience and technology companies to learn more about funding opportunities and hear success stories.According to the Arizona BioIndustry Association, our state is getting more federal funding for research and seeing higher job growth in the bioscience industry compared to the national average.“Tucson and Arizona are the international headquarters for the world’s only total artificial heart,” said Don Isaacs, SynCardia vice president of communications. “They replace the exact same parts of the heart as if you had a heart transplant.”The SynCardia heart is made in Arizona using bio-compatible material also made here. Isaacs says they have 82 employees in Arizona and about 80 people currently using the heart. The device is considered a bridge for people awaiting a transplant or a life saver for those who will not get transplants due to age or medical conditions.“There’s only 2,200 hearts available per year in the United States and the level of donors has been the same for the last twenty years,” Isaacs said.SynCardia is also undergoing FDA clinical trials for the world’s first wearable power supply for their temporary artificial heart. ©2007 The E.W. Scripps Co. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. (Republished with permission from ABC15) Read more: http://www.abc15.com/dpp/news/region_southeast_valley/tempe/Arizona-company-SynCardia-Systems-makes-worlds-first-total-temporary-artificial-heart#ixzz2X99ewU3x
Nasseo moves into the Fast Lane
Nasseo, Inc. is a start-up medical device company developing an implant surface modification technology to provide patients and clinicians with the next generation of dental and orthopedic implants. Over the past 18 months the company has achieved very impressive milestones and is in the Fast Lane to delivering a new platform technology that benefits patients in several compelling markets. In 2013 NASSEO was accepted into the BioInspire Medical Device accelerator in Peoria, AZ. In addition to mentoring and support, NASSEO received a $300,000 investment of seed funding from the highly competitive program. NASSEO was also named the 2013 Innovation Challenge Winner by the Arizona Commerce Authority (ACA) in its spring Arizona Innovation Challenge securing $250,000 for the commercialization of its first product, the TiArray™ Dental Implant which received FDA approval in 2013.
2012 AZBio Fast Lane Award Winner - Ulthera
Beauty and Growth – Ulthera, Inc Ulthera’s mission is to work with physicians to provide therapeutic ultrasound to improve the appearance and health of patients worldwide. The company is not only defined by its proprietary technology, but also its people. Ulthera’s team consists of experts in their respective fields who are aligned by the strength of the company’s mission and its leadership. Ulthera was founded in 2004 to leverage seven years of prior scientific research in therapeutic ultrasound for aesthetic and medical applications. In 2009, the Ulthera® System received FDA approval in the United States and is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. The first application for Ultherapy® – the procedure enabled by the System – is a non-invasive treatment of the face to achieve a brow lift. Ulthera’s robust scientific foundation and relentless pursuit of superior clinical outcomes have resulted in the rapid global uptake of the Ulthera platform. As Ulthera continues to develop and provide more applications for its platform, the company also remains committed to bringing value to physicians and their patients. In 2006, Matt Likens was hired as President and CEO of Ulthera by founder and owner Michael Slayton, Ph. D, with the expectation of obtaining FDA approval for Ulthera’s product and service (known as Ultherapy) within three months. Less than two years into his tenure at Ulthera, Matt found himself navigating this venture capital backed start-up though the worst economic downtown since the Great Depression. The Company also found itself facing an increasing skeptical and less commercially friendly US Food and Drug Administration (FDA) regime. With both of these risks significantly threatening the Company’s viability, Matt decided to change the Company’s regulatory pathway and focus by obtaining CE Mark from the European Union prior to obtaining FDA clearance. If this bet paid off, Ulthera’s regulatory runway would be significantly reduced and the Company would be able to generate sales in the European market. These revenues would also allow the Company to lessen the need to obtain additional venture capital financing thus reducing additional dilution to the Company’s current shareholders. While risky, the core of this decision was based on the multinational experience Likens attained at Baxter and his general entrepreneurial nature. The bet ultimately paid off. Today, Ulthera is a global, growth-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. More than 1,000 Ulthera Systems have been sold globally while treatments performed using the System have surpassed 100,000.
Yulex moves into the AZBio Fast Lane
http://www.yulex.com/ Rubber and commerce go hand in hand and rubber products are everywhere. Yulex Corporation is the global leader in guayule-based biomaterials for a wide range of markets and diverse applications. Yulex’s Guayule BioRubber Emulsions and BioRubber Solids have medical, consumer, and industrial applications to grow an increasingly diverse market community with ultra-pure, high-performance products. From medical devices to fabric coatings, and from bedding to industrial packaging adhesives, Yulex also provides technical and product development guidance and support, and even custom material compounding and formulation. Yulex Corporation, a technology, marketing and biomaterial product development company that applies sustainable crop science, clean bioprocessing, and materials science for the production of natural, allergy-friendly BioRubber derived from the renewable, crop Guayule was honored with the 2013 AZBio Fast Lane Award from the Arizona Bioindustry Association
W.L. Gore and Associaties, Inc. the 2013 Arizona Bioscience Company of the Year
W.L. Gore & Associates was honored at the 2013 AZBio Awards as the Arizona Bioscience Company of the Year by the Arizona Bioindustry Association in recognition of the development of the extensive Gore Medical family of products including vascular grafts, endovascular and interventional devices, and surgical meshes by its world class team of innovators in Flagstaff and Phoenix. In this video you will learn about Gore and also gain insights on what we need to do together to continue our Arizona Bioscience Industry growth from Gore's Kurt Long.
Ventana Medical Systems, Inc.05/17/2013
Ventana Medical Systems Introduction
Through innovative solutions for H&E, immunohistochemistry (IHC) and in situ hybridization (ISH), special stains, advanced workflow and digital pathology, Ventana empowers anatomic pathologists and laboratory professionals to increase testing efficiency. Our intuitive, integrated slide staining and workflow management platforms optimize laboratory operations to minimize errors, support diagnosis, and inform treatment decisions for anatomic pathology professional